Oglesby A, et al. Patient-reported outcomes after switching to a two-drug regimen of dolutegravir + rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies. Abstract P101. HIV/Drug Therapy Glasgow 2018.
Import en verspreiding van ESBL-E door internationale reizigers: COMBAT-studie
feb 2017 | Bacteriële infecties